Company: MNTR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001620
Chunk: 232

Company: Mentor Capital, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 232
---
per share and $1.60 per share, respectively. Mr. Billingsley paid the Company $14,347 in cash.

15

The
sale of 2,000,000 and 90,410 shares of common stock through the exercise of Series B and Series D warrants were made in reliance on 11
U.S.C. § 1145 and Section 3(a)(7) of the Securities Act of 1933, as amended.

Other
than as stated above, there have been no other unregistered securities sold within the past three years.

Item
6. [Reserved]

Item
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The
following discussion of our financial condition and results of operations for the years ended December 31, 2024, and 2023 should be read
in conjunction with the financial statements and the notes to those statements that are included elsewhere in this Annual Report on Form
10-K.

We
sold the entirety of our majority ownership interest in Waste Consolidators, Inc. (“WCI”) on October 4, 2023 for $6,000,000,
resulting in the elimination of our facilities operations segment at that time. Accordingly, the results of operations and assets and
liabilities for this segment were excluded from the Company’s continuing operations on December 31, 2023, and for all prior periods
of comparison and are presented as a discontinued operation in this report and in the Company’s Annual Report for the period ended
December 31, 2023 on Form 10-K as filed with the Securities and Exchange Commission on April 1, 2024.

Corporate
Background

Beginning
September 2008, after the name change back to Mentor Capital, Inc., the Company’s common stock traded publicly under the trading
symbol OTC Markets: MNTR and after February 9, 2015, as OTCQB: MNTR and after August 6, 2018, under the trading symbol OTCQX: MNTR and
after May 1, 2020, under the trading symbol OTCQB: MNTR.

In
2009, the Company began focusing its investing activities on leading-edge cancer companies. In response to government limitations on
reimbursement for highly technical and expensive cancer treatments and a resulting business decline in the cancer immunotherapy sector,
the Company decided to exit that space. In the summer of 2013, the Company was asked to consider investing in a